Scott Cullison Email & Phone Number

United States

Stride BDCom Consulting, LLC provides professional executive level business development (BD) and/or commercial planning (CP) strategic/tactical services in the biotech/pharma industry. BD Services are from pitch deck refinement and outreach, facilitating due diligence, through negotiation of term sheets/agreements, and even alliance management. CP Services range from broad portfolio indication prioritization, development of early-stage competitive landscape and TPPs, managing late-stage primary market research with physicians, KOLs, and payers (US & EU), and finally building robust product forecast and rNPV models with easy scenario analysis capabilities. Experience working across a broad range of therapeutic modalities (i.e., small molecules, monoclonal antibodies, cell/gene therapies, complex biologics, vaccines, RNA drugs, others) and therapeutic areas (i.e., Oncology, Hematology, Immunology, Neuroscience/Pain, Inflammation, Cardiovascular/Metabolic, Gastrointestinal/Genitourinary, Ophthalmology, Dermatology, Nephrology, Endocrinology, Infectious Diseases, Respiratory, Men's/Women's Health, Rare Diseases, others). Services range from smaller, defined project specific work to more common significant engagement to lead BD and/or CP activities driving toward successfully meeting corporate objectives and goals. Typical roles with clients may include acting or interim Chief Business Officer or SVP BD, Chief Commercial Officer or SVP CP, and serving on Business Advisory Boards.

Executed definitive agreement for Peloton to be acquired by Merck for $2.2 billion. Leadership of business development and commercial planning strategy and execution for portfolio of late-stage and preclinical oncology programs and a preclinical non-oncology asset. Effectively identify, develop and negotiate potential licensing or strategic deal opportunities with partners. Prepare commercial launch strategy plan for lead program entering Phase 3 for renal cell carcinoma (RCC) and in on-going Phase 2 for orphan indication of VHL disease associated RCC (now an approved product! Welireg). Departed company following integration/transition period with Merck after deal closed.

Cincinnati, Ohio, Us

Leadership of all business development strategy and tactical execution to explore partnership opportunities for clinical stage programs in ophthalmology and diabetic related complications (nephropathy, neuropathy, etc). Departed after company reorganized following Phase 2 clinical failure of lead program.

Houston, Texas, Us

Leadership of all global commercial planning activities and pre-launch strategic initiatives for late-stage gene modified T cell therapy product adjunctive to allogeneic hematopoietic stem cell transplant (HSCT) for orphan inherited blood disorders and malignant diseases. Responsible for aligning cross functional program research and development activities, strategic operational relationships, and commercial positioning and value messaging to ensure optimized development and launch planning. Drive strategic commercial and competitive intelligence activities for platform of TCR/CAR-T programs and portfolio planning for pipeline expansion. Report directly to CEO and a member of Executive Committee.Developed commercial planning strategy and conduct all global market research, market access, market development, sales forecasting, and commercial capability planning in support of pre-launch activities for Phase 2/3 gene-modified T cell therapy enabling a curative transplant for multiple orphan diseases and treatment for malignancies. Highly complex stem cell transplant landscape and adoptive cell therapy product requires creative commercial approach and challenges to be addressed including value messaging, pricing, reimbursement models, manufacturing/COGS, and distribution.

Winston-Salem, Nc, Us

Leadership of all business development activities related to identifying, developing and negotiating potential out-licensing, in-licensing and strategic deal opportunities. Reported directly to CEO and a member of Executive Committee. Executed a robust strategic process to identify, evaluate and negotiate potential strategic opportunities for company. Ultimately entered into definitive agreement for a reverse merger with a private company.Consistent with evolving out-licensing strategy, proactively identified potential companies with strategic interest and capabilities in relevant therapeutic areas, built and presented overviews of product opportunities, facilitated due diligence and fostered key decision-maker relationships, negotiated business and financial terms and ultimately align to secure a value-creating deal.Consistent with evolving in-licensing strategy, proactively identified available opportunities meeting defined criteria, performed initial screen to determine merits of further evaluation, facilitated cross-functional due diligence, negotiated business and financial terms and ultimately to secure an agreement.

Winston-Salem, Nc, Us

Identified, developed, and negotiated potential R&D and commercial strategic collaborations. After securing collaboration with AstraZeneca for a compound in development for major depressive disorder in December 2009, served as the Development Liaison and Alliance Manager to lead compound in all aspects of development and pre-launch commercial activities. Leader in driving overall strategy and coordination of true co-development collaboration that executed over a two-year period a major Phase 3 program in depression that included four pivotal trials and one long-term safety study that collectively screened over 8000 subjects, a Phase 2 trial and multiple Phase 1 studies. As a member and key voice on each of clinical, regulatory, and pharmaceutical development teams, steered strategy and quality execution of clinical and medical operations, worldwide regulatory strategy and interactions, NDA package preparedness, and drug development and supply. Appointed as Therapeutic Area Leader for mood disorders. Roles and responsibilities included: developing and championing therapeutic area strategies based on current science and clinical practice, KOL input, competitive environment, and market dynamics; preparing and maintaining Target Product Profiles; creating a project ‘dossier’ that captured critical information needed to drive value; recommending communication strategy & content; developing in- and out-licensing strategies to facilitate partnering efforts; anticipating potential problems and/or conflicts and developing strategies and tactics to address them; and communicating up-to-date Therapeutic Area information, keeping all major stakeholders informed.

Winston-Salem, Nc, Us

Identified, developed, and negotiated potential R&D and commercial strategic collaborations. In second half 2009, ran a competitive auction process for a Phase 3 ready compound for depression with most major pharmaceutical companies. Co-ordinated due diligence and term sheet proposals then negotiated contracts in parallel with multiple selected companies. Ultimately, executed deal with AstraZeneca for $200 million upfront, over $1 billion in milestones and significant double-digit royalties. Targeted GSK Center of Excellence of External Drug Discovery (CEEDD) as ideal partner for risk-sharing deal structure that fit company strategy and closed $1.5 billion strategic collaboration in July 2007. Actively searched for in-licensing opportunities that fit evolving corporate strategy. Performed initial technical and commercial evaluation, managed further scientific review and due diligence, and negotiated term sheets. Oversaw and managed operations of company’s only commercial product, Inversine (mecamylamine HCl). Worked closely with cross-functional team to address manufacturing, distribution, sales, accounting and regulatory items. Performed analysis and implemented product pricing changes to maximize revenues. Project team leader for variety of important pipeline compounds at various stages of development, including preclinical, Phase 1 and late-stage Phase 2/3 compound. Recognized leader by executive team that would appoint me to manage most important projects.

Winston-Salem, Nc, Us

Identified, developed, and negotiated potential R&D and commercial strategic collaborations. Completed major, company transforming deal with AstraZeneca for cognitive disorders and schizophrenia. Contract included a license for lead molecule in Phase 2, a robust 4-year research collaboration, an option agreement related to other targets, a right of first negotiation for other specified indications, and a co-promotion and potential product quid agreement. Led cross-functional team through initial presentations, term sheet discussions, comprehensive due diligence evaluation and key member of negotiation team. Developed and negotiated numerous potential collaborations and out-licensing transactions. Responsible for coordinating and leading due diligence with cross-functional groups. Anticipated and proactively addressed issues and questions from potential partners. Performed deal comparable and valuation analysis, drafted deal structure and terms, and negotiated potential licensing transactions with numerous parties simultaneously. Also responsible for critically assessing and negotiating potential in-licensing opportunities.Managed company’s marketed product, Inversine, including oversight of manufacturing, packaging, distribution, marketing, and sales. Facilitated FDA and Medicaid reporting requirements. Provided strategic business development and commercial perspectives on numerous cross-functional project teams and committees. Developed product profiles, competitive assessments and commercial forecasts for pipeline candidates. Initiated and led compound portfolio optimization analysis and recommendations.

Winston-Salem, Nc, Us

Identified, developed, and negotiated potential R&D and commercial strategic collaborations. Co-lead in overseeing due diligence, financial analysis, and contract negotiation in acquisition of a marketed product, Inversine. Managed transition of all assets related to the acquisition, product re-launch, and continued to oversee all product related responsibilities as product manager. Identified potential partners, coordinated due diligence, performed deal comparable and valuation analysis, drafted deal structure and term sheets, and negotiated potential agreements with major pharmaceuticals, biotechnology companies, and academic institutions. Conducted competitive intelligence, market research, and product forecasts to appraise portfolio opportunities and make recommendations to executive team in comprehensive Product Optimization Plans.

Mba

Bachelor Of Science (Bs), Molecular And Cellular Biology